Obesity is quickly becoming one of Western society's great epidemics [1, 2] . The well documented association of obesity with a number of disease states, including atherosclerosis, hypertension, insulin resistance, etc. (collectively termed as 'metabolic syndrome') [3] and more recently cancer [4] , has increased interest on the mechanisms through which obesity exerts these effects. Earlier studies have demonstrated that chronic obesity is associated with immune dysregulation reminiscent of lowgrade inflammation characterized by increased macrophage infiltration into adipose tissue as well as increased expression of proinflammatory cytokines from fat cells [5] [6] [7] [8] [9] . These observations stimulated discussion suggesting that obesity may affect the outcome or even the development of diseases in which inflammation plays a central role including inflammatory bowel disease (IBD) [10] . IBD is used to describe two pathological conditions, namely Crohn's disease and ulcerative colitis, where intestinal inflammation is a major component. Indeed, a number of fat derived molecules, termed adipokines, are involved in the development of intestinal inflammation in several animal models [11] [12] [13] [14] . Interestingly, in the case of Crohn's disease the extent of inflammation and histological damage are correlated with the development of a fat mass (of mesenteric origin) that wraps the intestine, termed 'creeping fat' [15] . As is the case with obesity, Crohn's disease-associated 'reeping fat' is also characterized by infiltration of fat depots with immune cells and increased levels of proinflammatory cytokines, such as IL-6 and TNFa, secreted in part by adipocytes [16] .
Substance P is an 11 amino acid peptide and a member of the tachykinin family of peptides [17] . It interacts with the G protein-coupled neurokinin receptor family, primarily with the high affinity neurokinin-1 receptor (NK-1R) and to a lesser extent with NK-2R and NK-3R. SP-NK-1R interactions mediate neurogenic 
Purpose of review
The purpose of this review is to present recent data on the effects of substance P on the development of two common pathological conditions, namely obesity and gut inflammation, and elucidate the role of this neuropeptide as a potential regulator between increased adiposity and exacerbated inflammatory responses during inflammatory bowel disease.
Recent findings
We present data that demonstrate a role for substance P in both obesity and inflammatory bowel disease and investigate potential effects on fat tissue that may influence the progression of intestinal inflammation. More specifically, we discuss new evidence for direct effects of substance P on fat tissue that determine fat depot size and overall weight in mice and analyze some of the potential mechanisms. Furthermore, we present data that describe changes in the intestinal sensory innervation, in particular substance P-positive innervation, during gut inflammation and new direct evidence of the effects of preestablished obesity in the outcome of experimental inflammation of the colon in mice. In the end we propose a link between the role of substance P in the promotion of obesity and the potential consequences on inflammatory bowel disease.
Summary
We propose that substance P may promote fat tissue expansion either centrally or peripherally and thus create a proinflammatory environment (as is the case with obesity) which may in turn affect the progression (exacerbate) of gut inflammation. Further studies are required on the effects of 'creeping fat' in inflammatory bowel disease in order to decipher the role of this type of fat-depot expansion in the development of the disease. inflammation [18, 19] , intestinal motility [20] , mucosal permeability [21] , epithelial ion transport, and colonocyte proliferation [22, 23] . The identification of the substance P in fat depots [24, 25] , representing the first evidence for sensory innervation of adipose tissue, as well as the reduction in epididymal and retroperitoneal adiposity after capsaicin-induced sensory neuron desensitization [26] , suggest that this neuropeptide may exert effects on adipocytes and possibly other cells within the fat depots. Recently, using an experimental model of colitis 2,4,6, trinitrobenzene sulfonic acid (TNBS) reminiscent of Crohn's disease, we observed significant inflammatory changes in the mesenteric fat depots of mice and demonstrated the potential involvement of substance P in the generation of proinflammatory responses in adipose tissue that may participate in IBD pathogenesis [27] . This represented the first demonstration that gut inflammation is accompanied by profound inflammatory changes in the adjacent mesenteric fat depots characterized by inflammatory cell infiltration, elevated cytokine levels and increased NK-1R transcription. These results also provided strong evidence linking substance P, adipose tissue, and intestinal inflammation.
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Substance P and gut inflammation
The distribution of neurokinin receptors in different cell types, both in the small intestine and colon [28] [29] [30] [31] underlines the importance of these receptors in gastrointestinal function. Moreover, changes in the abundance of these receptors, coupled with their proinflammatory potential following ligand stimulation, are expected to affect physiological functions of this tissue. Indeed, several lines of evidence support an important role for substance P in the generation of intestinal inflammation [32] [33] [34] . In a recent study, Straub et al. [35 ] observed a decreased number of sympathetic nerve fibers in all layers of the colon of patients with Crohn's disease as well as the colon of the dextran sulfate sodium (DSS) and IL-10À/À animal models of IBD colitis. In contrast, the number of substance P-positive nerve fibers increased in the same patients along with the concentration of the sympathetic nerve repellent factor SEMA3C in the colonic crypts of these colitis models. In a separate study, the number of substance P immunoreactive nerve fibers was increased in rectosigmoid biopsies collected from patients with irritable bowel syndrome (IBS) [36 ] . Although the exact role of substance P in the development of these diseases is yet to be determined, its ability to induce cytokine expression from different cell types [27, [37] [38] [39] provides plausible support for such a role.
Another possible explanation for the role of substance P in the pathogenesis of intestinal inflammatory diseases comes from recent data from our group showing effects of substance P on angiogenesis. The importance of angio-genesis in the development of IBD has been established by Danese et al. [40] who demonstrated substantial angiogenic activity in the mucosa of both ulcerative colitis and Crohn's disease patients. In our group, Koon et al. [41 ] have established a link between substance P and angiogenesis in the intestine by showing increased expression of the angiogenic factor CCN1 in colonocytes in response to substance P administration. In the same study, CNN1 was found to be elevated in the colon of patients with Crohn's disease and ulcerative colitis as well as in the DSS mouse model of colitis. Furthermore, inhibition of NK-1R signaling led to decreased CCN1 levels in the colon of DSS-exposed mice. Collectively, these data suggest a proangiogenic role (in addition to the already established proinflammatory role) for substance P during colitis in both humans and animal models. Interestingly, angiogenesis is closely related to the development of adipose tissue and adipocyte-endothelial cell interactions are presumed to be involved in the development and maintenance of adipose tissue [42, 43] . As human mesenteric preadipocytes express NK-1R [27] it is possible that SP-NK-1R interactions to stimulate the release of proangiogenic factors that can participate in fat depot expansion during obesity, colitis, and IBD.
Substance P and obesity
The control of food intake and energy balance is achieved through complex interactions between numerous hormones, signaling molecules and other intracellular effectors, and variety of neuropeptides together with their collective receptors [44, 45] . Obesity and its related pathologies are a result of a disruption in this balance. Despite its role in gastric motility and digestion [46] , the presence of substance P in the stomach, duodenum, and jejunum and the participation of a host of other neuropeptides in the regulation of food intake [44] , very little evidence existed to suggest involvement of substance P in the development of obesity and the regulation of metabolic processes. In a recent study, we have demonstrated the potential of substance P to regulate food intake centrally, as well as its ability to act through NK-1R on fat cells at the peripheral level, and exert effects in body weight and associated metabolic responses [47 ] . We showed that substance P had moderate effects on appetite and disruption of SP-NK-1R interactions by a specific NK-1R antagonist, leads to reduced weight gain in a high fat diet feeding mouse model and to weight loss in the diet induced and the leptin deficient, ob/ob mouse models of obesity [47 ] . Furthermore, reduced weight was accompanied by improved responses of these animals to glucose and insulin challenges, thus reversing a prominent obesity-related pathology, namely insulin resistance. As mentioned earlier, these effects may be due to both central and peripheral actions of substance P on fat tissue components (demonstrated in this study by the discrepancy in fat-depot size between the inhibitor receiving and its pair fed counterpart group, in the diet-induced obesity model). Indeed, this potential of substance P to directly signal on adipose tissue components has already been demonstrated in our previous study [27] .
Our latest data show the ability of substance P to affect fat tissue mass through effects on both preadipocyte replication and apoptosis (Gross et al. AJP, in preparation). In this study we observed that substance P treatment led to increased preadipocyte replication via the activation of a number of intracellular molecules and membrane receptors and that this increase is both Akt and a PKCu dependent. Finally, we demonstrate that substance P-induced NK-1R-dependent preadipocyte rescue of apoptosis in response to Fas-L is likely due to reduced poly(ADP-ribose)-polymerase (PARP) and caspase-7 cleavage as well as reduction of caspase-3 activation. This is in agreement with the results from a previous study demonstrating that removal of sensory neurons increase adiposity in certain depots suggesting that sensory innervation of white adipose tissue is essential for its homeostasis. Along with these data, the ability of substance P to signal through its high affinity NK-1R receptor in adipose tissue components underlies its potential to affect fat depot growth overall, with the latter constituting a major physiological change observed in patients with Crohn's disease.
Gut inflammation and obesity
We have mentioned earlier the ability of fat cells to produce numerous inflammatory components as well as the ability of fat tissue to recruit inflammatory cells. There is sufficient data that suggests that certain nutrients as well as dietary habits may be associated with the risk of developing IBD. Such habits include consumption of high levels of sugars as well as fat from animal origin [48, 49] , two major sources of energy associated with obesity. Perhaps the most direct experimental evidence for the effects of increased adiposity in the outcome of intestinal inflammation have been provided by a recent study showing that high fat feeding of mice before induction of experimental colitis disrupted the balance between regulatory T cells and natural killer T cells thus exacerbating the outcome of the disease [50 ] . In this model, animals kept in high fat diet exhibited increased number of natural killer T cells, which, compared with natural killer T cells isolated from animals on normal diet, produced higher amounts of TNFa and IFNg, whereas the numbers of the regulatory T cells was significantly decreased. Furthermore, adoptive transfer of regulatory T cells rescued both increased colitis and increased cytokine levels observed in the high-fat diet group. In a similar paradigm of chemically induced inflammation researchers found that high-fat diet promoted caeruleininduced pancreatitis in doses that were noninflammatory in mice under normal diet [51 ]. However, pancreatitis was significantly reduced in animals injected with an adiponectin-expressing adenovirus. Interestingly, adiponectin is an adipocytokine with lower expression in the hypertrophic fat depots of obese individuals [52] and higher expression in the mesenteric fat depots of patients with Crohn's disease [14] . It is thus evident that increases of abdominal fat mass may influence the severity of gut inflammation or even contribute as an initial trigger in the generation of such diseases.
Furthermore, IBD patients exhibit elevated cytokine and endotoxin (LPS) levels in their circulation and these factors are also thought to be central to the activation of inflammatory cells that participate in the development of these diseases. In two separate studies, endotoxemia was related to food intake [53] , as well as obesity and insulin resistance in mice [54] . In the later study, high-fat diet also increased the numbers of LPS-positive microbiota in the gut. Furthermore, in mice, LPS treatment produced similar changes in adipose tissue, liver size and insulin resistance, as did high-fat diet. Therefore, such data reinforce the notion that obesity and changes in fat tissue overall are important factors in the outcome of inflammatory conditions of the intestine.
Conclusion
On the basis of the studies described in this review, there is persuasive evidence associating the neuropeptide substance P with two very common and rapidly growing pathologies of the last two decades, namely obesity and IBD. The mechanisms underlying these potential effects are still unclear, but accumulating evidence demonstrate the ability of substance P to stimulate proinflammatory responses in different cell types involved in these conditions. In addition, new potential pathways are suggested by its ability to influence angiogenesis and fattissue growth. The latter can be accomplished in multiple ways through the effects of substance P on preadipocytes replication and apoptosis. As increased preadipocyte numbers are essential for fat depot enlargement, the direct effect of substance P on these cells strongly favors such a development (summarized in Fig. 1 ). Another way substance P could affect fat growth is through its ability to increase angiogenesis, although these studies have not yet been performed in the context of fat tissue. Furthermore, it is also becoming clear that the proinflammatory environment that exists with increased adiposity is favorable for the development of conditions where inflammation represents a central component, such as IBD. Thus, substance P seems to be able to influence the development of intestinal inflammation both directly, through the activation of proinflammatory pathways, and indirectly through its actions on fat tissue that may disrupt fat tissue homeostasis, including the promotion of obesity. As more of these pathologies continue to be investigated under the scope of preexisting obesity, changes in responses of fat tissue components to endocrine signals will be of central importance in the efforts to comprehend the mechanisms underlying these diseases and in future attempts for potential treatments. The increasing incidence of IBD and the continuously decreasing age at which symptoms for this disease first appear, point to environmental and habitual factors as potential reasons for this phenomenon. Increased energy intake and the subsequent development of obesity (with its pathological consequences) is becoming a major epidemic. Importantly, factors such as substance P and possibly other neuropeptides that are common between these two conditions may prove helpful in uncovering causes as well as developing future therapeutic approaches. PMNs SP levels increase in the intestinal mucosa during inflammation and signal to the proximal mesenteric fat depots via the destruction of the intestinal wall (alternatively fat cells may be exposed to SP through sensory neurons innervating these depots). Such an exposure may then lead to increased preadipocyte proliferation and the subsequent fat depot expansion observed in CD (as well as in our experimental models of TNBS colitis). Finally, SP induced increases in IL-8 expression may lead to neutrophil recruitment that in turn has the potential to induce the recruitment of several other inflammatory cells via release of other proinflammatory cytokines. CD, Crohn's disease; SP, substance P; TNBS, 2,4,6, trinitrobenzene sulfonic acid.
